New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
19:03 EDTSYNSynthetic Biologics reiterates collaboration with Intrexon still in effect
Synthetic Biologics reiterated that the exclusive channel collaboration agreement dated August 6, 2012 between the company and Intrexon remains in effect. This agreement governs a "channel collaboration" arrangement for the use of Intrexon's technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases.
News For SYN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
09:18 EDTSYNOn The Fly: Pre-market Movers
Subscribe for More Information
07:00 EDTSYNSynthetic Biologics initiates SYN-010 Phase 2 clinical trial
Synthetic Biologics reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation, or IBS-C. This is a placebo-controlled study to evaluate the ability of two dose strengths of SYN-010 to reduce the production of methane in breath methane-positive patients with IBS-C. Breath methane is strongly associated with constipation in IBS-C and higher methane levels are proportional to constipation severity. This Phase 2, randomized, double-blind, parallel-group, placebo-controlled, multi-dose study is expected to be conducted at multiple centers in the United States. The primary objective of this study is to evaluate the change from baseline in breath methane, as determined by a lactulose breath test, in methane-positive patients with IBS-C after seven days of treatment with one of two formulations of SYN-010 compared with placebo. Approximately 60 patients will be enrolled and randomly assigned in a 1:1:1 ratio to one of three groups, including two different SYN-010 dose groups and a placebo group. Patients are scheduled to receive single oral doses of SYN-010 each day for 28 days.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use